On August 6, 2016, the first pair of participants received an experimental treatment session in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for treating PTSD. This dyad was officially enrolled on August 5. Led by Principal Investigator Michael Mithoefer, M.D., and Sub-Investigator Candice Monson, Ph.D., this is a pilot Phase 1/Phase 2 open-label study exploring CBCT integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). Dr. Monson is a leading expert on individual and conjoint cognitive therapies to treat PTSD.
The study will enroll 10 dyads, each pair with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. This is the first MAPS-sponsored MDMA study to employ measures developed for the DSM-5. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The study has received approval from all necessary government agencies, and will begin screening local participants residing around South Carolina for enrollment this summer. Learn more…
